Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: Review and consensus statement

Lawrence H. Einhorn, Bernardo Rapoport, Jim Koeller, Steven M. Grunberg, Petra Feyer, Cynthia Rittenberg, Matti Aapro

    Research output: Contribution to journalReview articlepeer-review

    33 Scopus citations

    Abstract

    The objective of this paper is to evaluate the efficacy of modern antiemetic therapy for chemotherapy-induced nausea and vomiting for patients receiving multiple-day or high-dose chemotherapy. Published phase II and phase III studies as well as their personal experiences were evaluated by the authors to develop this consensus statement. The largest published experience with multiple-day chemotherapy is with 5-day cisplatin combination chemotherapy. The introduction of 5-HT3 antagonists greatly improved emetic control. However, day 4-5 nausea as well as delayed nausea and vomiting remains a clinical problem despite the inclusion of dexamethasone. A 5-HT3 antagonist plus dexamethasone is the preferred current option for patients receiving high-dose chemotherapy with stem cell transplant. However, the results do not appear as successful as for highly emetic standard-dose chemotherapy.

    Original languageEnglish (US)
    Pages (from-to)112-116
    Number of pages5
    JournalSupportive Care in Cancer
    Volume13
    Issue number2
    DOIs
    StatePublished - Feb 1 2005

    Keywords

    • 5-HT3 antagonist
    • Antiemetics
    • High-dose chemotherapy
    • Multiple-day chemotherapy

    ASJC Scopus subject areas

    • Oncology

    Fingerprint Dive into the research topics of 'Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: Review and consensus statement'. Together they form a unique fingerprint.

    Cite this